Thursday, November 12, 2026

USD/JPY Went Down By Over 10% In The Last 21 Sessions

USD/JPY Went Down By Over 10% In The Last 21 Sessions

(VIANEWS) - USD/JPY (USDJPY) has been up by 10.23% for the last 21 sessions. At 20:10 EST on Tuesday, 6 August, USD/JPY (USDJPY) is $144.84.

USD/JPY's yearly highs and lows, it's 3.245% up from its 52-week low and 10.559% down from its 52-week high.

Volatility

USD/JPY's last week, last month's, and last quarter's current intraday variation average was a negative 0.96%, a negative 0.42%, and a positive 0.41%, respectively.

USD/JPY's highest amplitude of average volatility was 0.96% (last week), 0.60% (last month), and 0.41% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/JPY's Forex is considered to be overbought (>=80).

Previous days news about USD/JPY (USDJPY)

  • Usd/jpy: cautious of getting carried away – OCBC. According to FXStreet on Monday, 5 August, "We also noted how the recent decline in USD/JPY saw a recoupling of the FX to UST-JGB yield differentials. ", "Back during May - Jul, USD/JPY had earlier traded much higher while UST yields and UST-JGB yield differentials went the other way lower."
  • Usd/jpy price forecast: consolidates around 144.00 after over 1.60 % loss. According to FXStreet on Monday, 5 August, "Conversely, if USD/JPY extends its losses below 144.00, the next support would be the January 9 pivot low at 143.42, ahead of the August 5 bottom at 141.69.", "This witnessed the USD/JPY drop over 4.90% during the Asian session to a low of 141.69 before trimming some losses and regaining the 144.00 mark. "
  • Usd/jpy struggles to extend recovery above 146.40 due to yen’s safe-haven appeal. According to FXStreet on Tuesday, 6 August, "The USD/JPY pair faces pressure in an attempt to extend recovery above the intraday resistance of 146.40 in Tuesday's European session. "

More news about USD/JPY (USDJPY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com